psychedelics
Ketamine One’s KGK Science Acquisition Provides Numerous Benefits
KetamineOne Capital Ltd. (NEO: MEDI) (OTC: KONEF) (FFT: MYO) (“Ketamine One” or the “Company”), a North American leader in mental health treatments with a growing network of clinics, recently announced that its newly acquired and wholly-owned subsidiary, KGK Science, has over US$2.3 million in net new revenue being secured from the month of July, […]
Silo Pharma Secures Patent that May be Used for Psychedelics Delivery Technology
Silo Pharma’s notice of allowance paves the way toward clinical trials for its psychedelics delivery platform using homing peptides. Silo Pharma Inc. (OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Patent Office issued a notice of allowance for its technology/method patent covering an isolated homing […]
Calgary, Alberta–(Newsfile Corp. – August 5, 2021) – Psygen Industries Ltd. (“Psygen” or the “Company”) announced today that it has closed its previously announced non-brokered private placement financing (the “Offering”) of unsecured convertible debentures (the “Debentures”) for gross proceeds of $5.5 million. The Debentures incur interest of 8.0% per annum. The proceeds will allow Psygen to hire key […]
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB: CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, is pleased to announce that it has closed its previously announced overnight marketed offering (the “Offering”) including the exercise in full of the over-allotment option granted to the Underwriters (as defined herein). In connection with the Offering, the […]
Medxtractor Doubles Down on B2B Licensing & mHealth
Medxtractor Corp. (CSE: MXT) (OTCQB: MXTTF) is known for its award-winning extraction equipment, but recently, the company refocused its efforts on its proprietary health-related databases, machine learning analysis, and plans to engage in B2B licensing and mHealth. Mental health disorders are notoriously difficult to diagnose and treat. Unlike most other ailments, there isn’t a simple […]
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Genetic Screening Platform Technology and Data to Strengthen Entheon’s Psychedelic-Assisted Protocols Vancouver, British Columbia–(Newsfile Corp. – July 30, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“) is pleased to announce that the Company completed its acquisition of Lobo Genetics Inc. (“Lobo“), a personalized genetics company with a […]
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received approval for the listing of its common shares on the NYSE American LLC stock exchange (“NYSE American”). The Company expects its common shares will open for trading on the NYSE American on or […]
Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw
Vancouver, British Columbia–(Newsfile Corp. – July 28, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company“), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce the addition of Dr. Andrew (Andy) Greenshaw, Professor of Psychiatry and Neuroscience and Associate Chair (Research) for Psychiatry […]
VANCOUVER, British Columbia, July 22, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU ), an emerging biotech company focused on developing compounds to treat neurological conditions, is pleased to announce funding of its joint application with Dr. Argel Aguilar-Valles at Carleton University (“Carleton”) Department of Neuroscience by the Accelerate program at Mitacs […]
Mydecine Expands Portfolio of Novel Molecules Filing New Patent for MDMA-like Compounds
DENVER, July 21, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, today announced that the Company has filed a new patent for MDMA-like compounds further expanding its […]
Psyched Wellness Successfully Completes Its Largest Extraction and Shipment of AME-1 to Asia
Toronto, Ontario–(Newsfile Corp. – July 22, 2021) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (the “Company” or “Psyched”), a life sciences company focused on the production and distribution of artisanal functional and psychedelic mushrooms, is pleased to announce that the company has completed its largest extraction of AME-1 to date, and has successfully shipped […]
Cybin Announces Conditional Listing Approval from NYSE American
July 21, 2021 08:37 PM Eastern Daylight Time TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”). Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE […]
Cybin Announces Conditional Listing Approval from NYSE American
TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has received conditional listing approval from the NYSE American LLC stock exchange (the “NYSE American”). Doug Drysdale, Cybin’s CEO, added, “Conditional listing approval on the NYSE American is an important milestone in Cybin’s growth […]
Levitee currently operates two units, Sporeo Supply and Monk-E Nutraceuticals, while aggressively targeting cash flowing wellness assets through accretive M&A Multiple letters of intent executed for acquisitions of addiction & pain clinics, pharmacies, an omnichannel superfoods and supplements brand and a late-stage applicant for a Health Canada Dealer’s License Over CDN$12 million raised to date […]
PsyBio Therapeutics Announces Uplisting to OTCQB Venture Market
OXFORD, Ohio and COCONUT CREEK, Fla., July 14, 2021 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), an intellectual property driven biotechnology company developing novel formulations of psychoactive medications produced by genetically modified bacteria for the treatment of mental health challenges and other disorders, is pleased to announce that its […]
Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol “SILFF”
TORONTO, July 13, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“ Silo Wellness ” or the “ Company ”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, announces that its common shares are now trading on the OTCQB® Venture Market under the symbol “SILFF”. The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international […]
Silo Wellness Announces Approval for Trading on the OTCQB Under Symbol “SILFF”
TORONTO, July 13, 2021 (GLOBE NEWSWIRE) — Silo Wellness Inc. (“Silo Wellness” or the “Company”) (CSE: SILO) (OTCQB: SILFF) (FRA: 3K70), a leading global psychedelics company, announces that its common shares are now trading on the OTCQB® Venture Market under the symbol “SILFF”. The OTCQB® Venture Market is for entrepreneurial and development stage U.S. and international […]
Cybin Files its 13th Patent Application and Announces Digital Therapeutics Strategy
Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed its 13th new provisional patent application and has advanced the build-out of its digital therapeutics strategy. The company is evolving its programs beyond the psychedelic molecule, into an eco-system that may potentially drive […]
MedXtractor’s Reference Database Sets the Stage for SHAMAN & YMI
Artificial intelligence is already transforming many parts of our everyday lives. For example, Netflix recommends movies we’d enjoy, Facebook identifies friends in photos, and Alexa understands voice commands. Yet, despite these recent advances, most experts agree that AI is only starting to scratch the surface of what’s possible. According to Grand View Research, the global […]
BetterLife Provides H1 2021 Progress Update
VANCOUVER, British Columbia, July 12, 2021 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotechnology company primarily focused on developing compounds to treat neurological conditions, announces significant progress in H1 2021. TD-0148A BetterLife’s TD-0148A is a second-generation lysergic acid diethylamide (“LSD”) derivative molecule that has been synthesized […]
Real-world study expands access to MDMA-assisted therapy for patients with PTSD and concurrent disorders and will provide data on a regulated model for MDMA-assisted therapy VANCOUVER, BC, July 12, 2021 /CNW/ – Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased […]
Ketamine One Aims to Become a North American Mental Health Leader
Nearly one in five Americans were living with a mental illness or addiction in 2019, according to the National Institutes of Health. While the U.S. spends $16 billion on mental health treatments and ancillary services each year, challenges connecting with patients, significant adverse side effects, and other factors have made the problem difficult to overcome. […]
Atai Life Sciences N.V. Added to the North American Psychedelics Index
TORONTO, July 8, 2021 /CNW/ – Horizons ETFs Management (Canada) Inc. (“Horizons ETFs“) is announcing that Atai Life Sciences N.V. (“Atai Life Sciences“) has been included as a fast entry addition to the North American Psychedelics Index, (the “Index“), which is the underlying index of the Horizons Psychedelic Stock Index ETF (“PSYK“:NEO). The Index is designed to provide […]
Enveric Bio’s Acquisition of MagicMed Accentuates Strengths of Each Company
When two companies merge, or one is acquired by another, the reasoning behind the deal often falls into one of two categories. Either the companies are competitors with the merged entity grabbing a larger portion of their shared market, or they are complementary and perhaps working in adjacent fields. In either case, the strengths […]
Toronto, Ontario–(Newsfile Corp. – July 2, 2021) – Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the “Company“), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and under-served health problems, today announced that it has retained Edge Growth Holdings Corporation (“Edge Communications Group” or “Edge“) for […]
MedXtractor Fills a Key Gap in Mental Health Treatments
According to the Lancet Commission, mental health disorders are on the rise in every country worldwide, and the resulting lost productivity will cost the global economy $16 trillion by 2030. Yet, despite nearly two billion people with mental illness each year, these conditions are routinely misdiagnosed and inadequately treated. MedXtractor Corp.’s (CSE: MXT) (OTC: […]
Ehave Looks to Power the Psychedelics Revolution
Mental illness will cost the global economy $16 trillion by 2030 due to early-onset and lost productivity, with an estimated 12 billion working days lost due to these conditions each year. Conventional therapies have a mixed track record, but psychedelics have shown much promise in recent years. The challenge for researchers and medical professionals is […]
Diamond Therapeutics contracts BioPharma Services for Phase 1 clinical trial
TORONTO, June 17, 2021 /PRNewswire/ – Diamond Therapeutics Inc. (“Diamond”), a leading drug development company focused on low-dose psychedelic therapies for mental health, is pleased to announce the selection of BioPharma Services Inc. (“BioPharma”), as the contract research organization (CRO) for its Phase 1 clinical trial. The proposed study, titled “A Randomized, Double-Blind, Single […]
Vancouver, British Columbia–(Newsfile Corp. – June 17, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon”), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) (“Silo Wellness”), a functional and psilocybin mushroom company and psychedelic wellness retreats operator, have signed a referral agreement (the “Agreement”), […]
VANCOUVER, British Columbia, June 16, 2021 (GLOBE NEWSWIRE) — AREV NANOTEC BRANDS INC. (CSE: AREV) (OTC: AREVF) (“AREV” or the “Company”) Through its subsidiary AREV Cambodia is pleased to announce the Company has completed its land survey and soil analysis for cultivation of mushrooms, moringa and breadfruit. Mr. Rem Sareub, Head of Agriculture for AREV […]
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.
Rob is the co-founding President of Pelorus Equity Group and has more than 18 years of experience in the real estate finance industry. Since the formation of Pelorus in 2010, he has raised more than $175,000,000 in secured real estate transactions. Rob’s primary role at Pelorus Equity Group is the development of strategic alliances with […]
Hero Technologies Inc. is a cannabis company working toward a vertically-integrated business model. The company owns a majority stake in BlackBox Systems and Technologies LLC, an aeroponic cannabis cultivation system that provides optimal growing conditions to enhance photosynthesis and cultivation of large flowering plants, creating increased harvest efficiencies. The company’s strategic business plan includes cannabis […]
Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
